SGT 001
Alternative Names: SGT-001Latest Information Update: 14 Apr 2023
At a glance
- Originator University of Missouri-Columbia
- Developer Solid GT
- Class Gene therapies
- Mechanism of Action Dystrophin replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 31 Dec 2022 Solid Biosciences has patent protection for SGT 001 in USA, and World, prior to December 2022
- 31 Dec 2022 Solid Biosciences has patents pending for SGT 001 in USA, and World, prior to December 2022
- 31 Dec 2022 Discontinued - Phase-I/II for Duchenne muscular dystrophy (In adolescents, In children) in United Kingdom (IV), prior to December 2022